Eli Lilly and Company (ETR:LLY)
752.30
-8.50 (-1.12%)
Mar 31, 2025, 2:44 PM CET
Eli Lilly and Company Revenue
In the year 2024, Eli Lilly and Company had annual revenue of $45.04B USD with 32.00% growth. Eli Lilly and Company had revenue of $13.53B in the quarter ending December 31, 2024, with 44.68% growth.
Revenue
$45.04B
Revenue Growth
+32.00%
P/S Ratio
n/a
Revenue / Employee
$958.36K
Employees
47,000
Market Cap
681.88B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 45.04B | 10.92B | 32.00% |
Dec 31, 2023 | 34.12B | 5.58B | 19.56% |
Dec 31, 2022 | 28.54B | 223.00M | 0.79% |
Dec 31, 2021 | 28.32B | 3.78B | 15.40% |
Dec 31, 2020 | 24.54B | 2.22B | 9.95% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Siemens Healthineers AG | 22.67B |
Merck KGaA | 21.16B |
Fresenius SE & Co. KGaA | 21.83B |
Bayer Aktiengesellschaft | 46.61B |
Sartorius Aktiengesellschaft | 3.38B |
Fresenius Medical Care AG | 19.34B |
Carl Zeiss Meditec AG | 2.08B |
Fielmann Group AG | 2.16B |
Eli Lilly and Company News
- 20 hours ago - Experimental Lilly drug cuts genetic heart disease risk factor by 94% in trial - Reuters
- 20 hours ago - Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a), by nearly 94% from baseline at the highest tested dose in adults with elevated levels - PRNewsWire
- 1 day ago - Eli Lilly Vs. Novo Nordisk: Which Is The Better Bargain For Investors - Seeking Alpha
- 2 days ago - Eli Lilly Stock Up 1% After Key Signal, Despite S&P 500's ~2% Drop - Benzinga
- 2 days ago - Eli Lilly Stock Up 1% After Key Signal, Despite S&P 500's ~2% Drop - Benzinga
- 2 days ago - European Drug Regulator Gives Thumbs Down To Eli Lilly's Alzheimer's Drug, Analyst Says It Is Incremental Win For Biogen - Benzinga
- 2 days ago - CHMP Recommends Against Approval of Eli Lilly's Kisunla Alzheimer's Drug -- Update - Market Watch
- 3 days ago - Tech slump deepens: Google and Meta lead declines, healthcare and energy show strength - Forexlive